Related references
Note: Only part of the references are listed.Predictors of hepatitis B surface antigen loss, relapse and retreatment after discontinuation of effective oral antiviral therapy in noncirrhotic HBeAg-negative chronic hepatitis B
Margarita Papatheodoridi et al.
JOURNAL OF VIRAL HEPATITIS (2020)
Pregenomic HBV RNA and Hepatitis B Core-Related Antigen Predict Outcomes in Hepatitis B e Antigen-Negative Chronic Hepatitis B Patients Suppressed on Nucleos(T)ide Analogue Therapy
Ivana Carey et al.
HEPATOLOGY (2020)
Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conferences
Markus Cornberg et al.
JOURNAL OF HEPATOLOGY (2020)
COMMENTARIES
K. Seng Liem et al.
GASTROENTEROLOGY (2020)
Limited sustained response after stopping nucleos(t)ide analogues in patients with chronic hepatitis B: results from a randomised controlled trial (Toronto STOP study)
Kin Seng Liem et al.
GUT (2019)
Combining hepatitis B core-related and surface antigens at end of nucleos(t)ide analogue treatment to predict off-therapy relapse risk
Yao-Chun Hsu et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2019)
Induction of IFN-λ3 as an additional effect of nucleotide, not nucleoside, analogues: a new potential target for HBV infection
Kazumoto Murata et al.
GUT (2018)
Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance
Norah A. Terrault et al.
HEPATOLOGY (2018)
Contrasting Timing of Virological Relapse After Discontinuation of Tenofovir or Entecavir in Hepatitis B e Antigen-Negative Patients
Christoph Hoener zu Siederdissen et al.
JOURNAL OF INFECTIOUS DISEASES (2018)
DARING-B: discontinuation of effective entecavir or tenofovir disoproxil fumarate long-term therapy before HBsAg loss in non-cirrhotic HBeAg-negative chronic hepatitis B
George Papatheodoridis et al.
ANTIVIRAL THERAPY (2018)
Longitudinal trends in renal function in chronic hepatitis B patients receiving oral antiviral treatment
Prowpanga Udompap et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2018)
EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection
JOURNAL OF HEPATOLOGY (2017)
Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients - FINITE study
Thomas Berg et al.
JOURNAL OF HEPATOLOGY (2017)
Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial
Marc Bourliere et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2017)
Clinical outcomes and predictors for relapse after cessation of oral antiviral treatment in chronic hepatitis B patients
Kyu Sik Jung et al.
JOURNAL OF GASTROENTEROLOGY (2016)
Discontinuation of oral antivirals in chronic hepatitis B: A systematic review
George Papatheodoridis et al.
HEPATOLOGY (2016)
Systematic review: cessation of long-term nucleos(t)ide analogue therapy in patients with hepatitis B e antigen-negative chronic hepatitis B
M. -L. Chang et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2015)
Adding Pegylated Interferon to Entecavir for Hepatitis B e Antigen-Positive Chronic Hepatitis B: A Multicenter Randomized Trial (ARES Study)
Willem Pieter Brouwer et al.
HEPATOLOGY (2015)
Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study
Patrick Marcellin et al.
LANCET (2013)
Sustained Responses and Loss of HBsAg in HBeAg-Negative Patients With Chronic Hepatitis B Who Stop Long-Term Treatment With Adefovir
Stephanos J. Hadziyannis et al.
GASTROENTEROLOGY (2012)
Share Paper
